Ultrasound and Photoacoustic Imaging of Colon and Rectal Tumor Tissue

Overview

The purpose of this pilot study is to a) explore the photoacoustic properties of normal, polypoid, and malignant colorectal tissue and b) demonstrate the functionality of a novel endorectal photoacoustic ultrasound probe in humans with rectal cancer. The study includes two parts. The initial exploratory portion will be conducted ex vivo with resected colon and rectal specimens immediately following surgical excision. Based on those findings, an endorectal probe will then be constructed to examine in vivo tumors. The investigators hypothesize that in vivo photoacoustic imaging will be capable of differentiating normal from malignant tissue.

Full Title of Study: “Pilot Study of Ultrasound and Photoacoustic Imaging of Colon and Rectal Tumor Tissue”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 31, 2024

Interventions

  • Device: Photoacoustic imaging, photoacoustic microscopy
    • Emerging technique in which a short-pulsed laser beam penetrates diffusely into a tissue sample, causing the release of acoustic waves due to a transient temperature rise The transient acoustic waves, or photoacoustic waves, are then measured around the sample by US transducers The resolution of the devices can be altered by changing the wavelengths of laser light and spectrum analysis of the receiver. In this manner, human colorectal pathology will be examined under multiple types of photoacoustic ranges (broadly termed photoacoustic microscopy and photoacoustic imaging) The study is strictly observational as specimen imaging will have no impact on the clinical decision-making for the participants
  • Device: Endorectal photoacoustic imaging probe
    • Based on data gathered in the ex vivo cohort of patients, an endorectal imaging device using coregistered photoacoustic and ultrasound imaging will be constructed. This probe will then be used to perform in vivo imaging among patients with rectal pathology intraoperatively. The study is strictly observational as specimen imaging will have no impact on the clinical decision-making for the participants

Arms, Groups and Cohorts

  • Ex vivo imaging
    • Patients with known adenomatous polyps or malignancies in the colon or rectum undergoing resection will be considered for enrollment Participation will include imaging of both normal and known pathologic portions of the specimen ex vivo immediately following resection. The specimen will then undergo fixation and standard pathologic evaluation, with subsequent correlation between imaging and pathologic findings. This data will also be used to develop a convolutional neural network (CNN) to assist in interpreting photoacoustic imaging data.
  • In vivo imaging
    • Patients with distal rectal lesions (benign or malignant tumors within 15cm of the anal verge) will be enrolled for the in vivo imaging portion of the study Participation will include an intraoperative, in vivo evaluation of the tumor with a novel endorectal photoacoustic ultrasound probe as well as ex vivo imaging post-resection as described above. Following the induction of anesthesia, patients will undergo a 20 minute endorectal imaging evaluation performed by their colorectal surgeon. After imaging, the patient will then undergo standard-of-care surgical resection of the rectum. The resection specimen will then be imaged ex vivo as performed in the “ex vivo cohort” of this study. For this portion of the pilot, enrollment will be limited to 40 participants

Clinical Trial Outcome Measures

Primary Measures

  • Area under the receiver operating curve (ROC)
    • Time Frame: Approximately 60 minutes
    • -The purpose of this study is to develop and pilot imaging technology that will aid in the differentiation of malignant from normal colorectal tissue. As such, the primary endpoint is the differentiating capability of the endorectal coregistered probe, to be measured as the AUC or area under the receiver operating curve. This primary endpoint to be measured in both the ex vivo and in vivo portions of this study. This will also be used to compare performance of the classification neural network with ultrasound alone compared to ultrasound coupled with photoacoustic techniques.

Secondary Measures

  • Characterize both in and ex vivo tissue samples with photoacoustic imaging
    • Time Frame: Approximately 60 minutes
    • This outcome will be measured qualitatively by comparing histologic findings to the experimental imaging. The critical features to be analyzed in each image are the cross-sectional structure of normal colorectal tissues in comparison to the loss of a layered structure and its corresponding evenly distributed vascular pattern in the setting of neoplasia.
  • Performance characteristics of the novel endorectal ultrasound probe as measured by number of adverse events
    • Time Frame: Approximately 60 minutes
  • Performance characteristics of the novel endorectal ultrasound probe as measured by evidence of tissue damage from the imaging laser
    • Time Frame: Approximately 60 minutes
  • Performance characteristics of the novel endorectal ultrasound probe as measured by time required to complete study
    • Time Frame: Approximately 60 minutes
  • Performance characteristics of the novel endorectal ultrasound probe as measured by variability in image production
    • Time Frame: Approximately 60 minutes

Participating in This Clinical Trial

Inclusion Criteria

  • Patients with adenomatous polyps or any stage colorectal cancer undergoing surgical resection without intraoperative frozen section analysis – Age >18 years – Able to provide informed consent Additional Inclusion Criterion for in vivo imaging -Lesion located within 15cm of the anal verge Exclusion Criteria:

  • Inability to provide consent – Collection of intraoperative specimen for frozen section analysis will disqualify patients from participation

Gender Eligibility: All

Minimum Age: 19 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Washington University School of Medicine
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • William Chapman, Jr., M.D., Principal Investigator, Washington University School of Medicine
  • Overall Contact(s)
    • William Chapman, Jr., M.D., 314-454-7177, chapmanjr@wustl.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.